Revolution Medicines, Inc. (RVMD)

Revolution Medicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	11.58	35.38	29.39
Revenue Growth (YoY)	-	-	-67.27%	20.38%	-31.62%
Gross Profit	-	-	11.58	35.38	29.39
Selling, General & Admin	195.04	97.3	75.62	40.59	30.45
Research & Development	987.33	592.23	423.14	253.07	186.95
Total Operating Expenses	1,182	689.52	498.77	293.66	217.4
Operating Income	-1,182	-689.52	-487.19	-258.28	-188.01
Interest Income	90.69	86.88	47.48	9.15	0.93
Interest Expense	-24.23	-	-	-	-
Other Non-Operating Income (Expense)	-15.4	1.8	-0.19	-	-0.01
Total Non-Operating Income (Expense)	51.07	88.68	47.29	9.15	0.92
Pretax Income	-1,131	-600.85	-439.89	-249.13	-187.09
Provision for Income Taxes	-	-0.75	-3.52	-0.42	-
Net Income	-1,131	-600.09	-436.37	-248.71	-187.09
Net Income to Common	-1,131	-600.09	-436.37	-248.71	-187.09
Shares Outstanding (Basic)	190	168	113	81	73
Shares Outstanding (Diluted)	190	168	113	81	73
Shares Change (YoY)	13.35%	48.24%	40.34%	10.74%	32.68%
EPS (Basic)	-5.95	-3.58	-3.86	-3.08	-2.57
EPS (Diluted)	-5.95	-3.58	-3.86	-3.08	-2.57
Shares Outstanding	197	185.9	164.68	90.41	74.14
Free Cash Flow	-913.73	-567.74	-358.3	-235.22	-153.71
Free Cash Flow Per Share	-4.81	-3.38	-3.17	-2.92	-2.11
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-4207.12%	-730.01%	-639.70%
Profit Margin	-	-	-3768.28%	-702.95%	-636.58%
FCF Margin	-	-	-3094.14%	-664.83%	-522.99%
EBITDA	-1,174	-681.9	-481.08	-253.24	-183.86
EBITDA Margin	-	-	-4154.36%	-715.77%	-625.57%
EBIT	-1,182	-689.52	-487.19	-258.28	-188.01
EBIT Margin	-	-	-4207.12%	-730.01%	-639.70%
Effective Tax Rate	0.00%	0.13%	0.80%	0.17%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q